We are live on ! Find out more
GNOM icon

Global X Genomics & Biotechnology ETF

63 hedge funds and large institutions have $128M invested in Global X Genomics & Biotechnology ETF in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

11% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 18

0% more funds holding

Funds holding: 6363 (0)

0.42% less ownership

Funds ownership: 16.84%16.41% (-0.42%)

8% less capital invested

Capital invested by funds: $138M → $128M (-$10.4M)

Holders
63
Holders Change
Holders Change %
0%
% of All Funds
0.99%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
20
Reduced
18
Closed
4
Calls
$17K
Puts
Net Calls
+$17K
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Northwestern Mutual Wealth Management
1
Northwestern Mutual Wealth Management
Wisconsin
$82.7M -$8.05M -160,999 -9%
PAG
2
Private Advisor Group
New Jersey
$11.8M -$479K -9,571 -4%
OCM
3
One Capital Management
California
$6.26M +$665K +13,294 +11%
Mirae Asset Global Investments
4
Mirae Asset Global Investments
South Korea
$4.16M -$435K -8,702 -9%
Lido Advisors
5
Lido Advisors
California
$3.99M +$68.6K +1,372 +2%
PGA
6
Portland Global Advisors
Maine
$2.81M +$60K +1,200 +2%
PFG
7
Prosperity Financial Group
California
$1.91M +$2.75K +55 +0.1%
RJFSA
8
Raymond James Financial Services Advisors
Florida
$1.84M +$227K +4,546 +14%
UBS Group
9
UBS Group
Switzerland
$1.25M -$22.4K -447 -2%
MWAM
10
Manhattan West Asset Management
California
$1.12M +$349K +6,985 +43%
IWM
11
IHT Wealth Management
Illinois
$1.12M +$134K +2,685 +13%
SWA
12
Sightline Wealth Advisors
Connecticut
$890K
MIG
13
McGuire Investment Group
Rhode Island
$872K -$254K -5,080 -22%
EWM
14
Elmwood Wealth Management
California
$811K +$42.3K +845 +5%
OAM
15
Oppenheimer Asset Management
New York
$588K +$18.4K +367 +3%
LPL Financial
16
LPL Financial
California
$529K -$140K -2,801 -20%
HighTower Advisors
17
HighTower Advisors
Illinois
$434K -$21.5K -429 -5%
SWP
18
Stratos Wealth Partners
Ohio
$432K +$90.1K +1,802 +25%
Rockefeller Capital Management
19
Rockefeller Capital Management
New York
$359K +$370K +7,400 New
AAS
20
Avantax Advisory Services
Texas
$300K -$23K -460 -7%
Qube Research & Technologies (QRT)
21
Qube Research & Technologies (QRT)
United Kingdom
$282K +$40K +799 +279%
BS
22
Banco Santander
Spain
$281K
ACS
23
Archford Capital Strategies
Illinois
$246K -$9.2K -184 -4%
Stifel Financial
24
Stifel Financial
Missouri
$223K -$83.3K -1,666 -27%
CAL
25
Capital Analysts LLC
Pennsylvania
$195K +$13.4K +267 +7%

GNOM Hedge Fund Activity: Q2 2023 in Review

63 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q2 2023, worth a combined $128M — down 7.5% from $138M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GNOM positions and 4 closed out — a net gain of 1 holder — while 20 added to existing stakes and 18 trimmed.

The largest buyer was One Capital Management, adding an estimated $665K. The largest seller was Northwestern Mutual Wealth Management, cutting an estimated $8.05M.

  • 63 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $128M of Global X Genomics & Biotechnology ETF stock for Q2 2023, down 7.5% quarter-over-quarter.
  • 5 funds opened new Global X Genomics & Biotechnology ETF positions in Q2 2023 and 4 closed out, a net change of +1 holder.
  • The largest Global X Genomics & Biotechnology ETF buyer in Q2 2023 was One Capital Management, an estimated $665K added.
  • The largest Global X Genomics & Biotechnology ETF seller in Q2 2023 was Northwestern Mutual Wealth Management, an estimated $8.05M sold.

Based on aggregated 13F filings for Q2 2023.